{"id":933639,"date":"2026-02-03T08:30:02","date_gmt":"2026-02-03T13:30:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/"},"modified":"2026-02-03T08:30:02","modified_gmt":"2026-02-03T13:30:02","slug":"alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/","title":{"rendered":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment<\/b><\/p>\n<p class=\"bwalignc\"><i>\u2013 The review provides strong scientific rationale to support Alto\u2019s drug development approach leveraging its Precision Psychiatry Platform \u2013<\/i><\/p>\n<p>MOUNTAIN VIEW, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAlto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, &#8220;Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments,&#8221; in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience\u2019s leadership team, Patricio O\u2019Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head of therapeutics, neuroscience at Janssen and a member of Alto\u2019s board of directors.<\/p>\n<p>\nThe article consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity\u2014spanning synaptic, cellular, and circuit-level dysfunction\u2014is a shared biological driver across multiple high-burden psychiatric disorders, including major depressive disorder, schizophrenia, PTSD, and addiction.<\/p>\n<p>\nThe review concludes that therapeutic efficacy across pharmacologic, neuromodulatory, and behavioral interventions consistently converges on restoration of neuroplasticity, supporting plasticity as a causal, measurable, and druggable mechanism, rather than a descriptive or correlational concept. This framework helps explain both treatment resistance and durable clinical response, and provides a unifying biological rationale for next-generation psychiatric drug development.<\/p>\n<p>\nThe authors further highlight a critical industry gap: the historical absence of translatable biomarkers that directly index plasticity changes in humans. Addressing this gap is positioned as essential to improving patient stratification, accelerating development timelines, and increasing probability of clinical success\u2014core elements of Alto\u2019s precision psychiatry platform.<\/p>\n<p>\n\u201cThese insights validate Alto\u2019s strategy of pairing therapies with objective, circuit-level biomarkers,\u201d said Amit Etkin, M.D., Ph.D., president and chief executive officer at Alto Neuroscience. \u201cMoreover, we believe this publication underscores Alto\u2019s leadership in translating rigorous neuroscience into differentiated, biomarker-driven clinical programs\u2014which underpin the Company\u2019s long-term platform value and relevance across multiple large psychiatric indications.\u201d<\/p>\n<p>\nThe article appears in the American Journal of Psychiatry (2026), and can be found online <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1176%2Fappi.ajp.20251212&amp;esheet=54412360&amp;newsitemid=20260203088315&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=012887f2f687ee4bd53d62d6eca7e942\">here<\/a>.<\/p>\n<p><b>About Alto Neuroscience<\/b><\/p>\n<p>\nAlto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto\u2019s Precision Psychiatry Platform\u2122 measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto\u2019s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201clook forward,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to statements regarding Alto\u2019s expectations about the potential benefits, activity, effectiveness, tolerability, and safety of its product candidates and Precision Psychiatry Platform (\u201cPlatform\u201d); Alto\u2019s expectations with regard to the general design and results of its research and development programs and clinical trials; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto\u2019s product candidates, and other important factors, any of which could cause Alto\u2019s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled \u201cRisk Factors\u201d in each of Alto\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and Alto\u2019s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 filed with the Securities and Exchange Commission (\u201cSEC\u201d) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.<\/i><\/p>\n<p><b>Availability of Information on Alto\u2019s Website<\/b><\/p>\n<p>\nAlto routinely uses its investor relations <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.altoneuroscience.com%2Foverview%2Fdefault.aspx&amp;esheet=54412360&amp;newsitemid=20260203088315&amp;lan=en-US&amp;anchor=website&amp;index=2&amp;md5=2731806c8aa25cb91d5abeccca0e9576\">website<\/a> to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260203088315\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260203088315\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Nick Smith<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@altoneuroscience.com\">investors@altoneuroscience.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:media@altoneuroscience.com\">media@altoneuroscience.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Neurology Mental Health Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260203088315\/en\/1266385\/3\/Alto_Neuroscience.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment \u2013 The review provides strong scientific rationale to support Alto\u2019s drug development approach leveraging its Precision Psychiatry Platform \u2013 MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, &#8220;Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments,&#8221; in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience\u2019s leadership team, Patricio O\u2019Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933639","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment \u2013 The review provides strong scientific rationale to support Alto\u2019s drug development approach leveraging its Precision Psychiatry Platform \u2013 MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, &#8220;Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments,&#8221; in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience\u2019s leadership team, Patricio O\u2019Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head &hellip; Continue reading &quot;Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T13:30:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment\",\"datePublished\":\"2026-02-03T13:30:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/\"},\"wordCount\":869,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/\",\"name\":\"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-03T13:30:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk","og_description":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment \u2013 The review provides strong scientific rationale to support Alto\u2019s drug development approach leveraging its Precision Psychiatry Platform \u2013 MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, &#8220;Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments,&#8221; in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience\u2019s leadership team, Patricio O\u2019Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head &hellip; Continue reading \"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T13:30:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment","datePublished":"2026-02-03T13:30:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/"},"wordCount":869,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/","name":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-03T13:30:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203088315r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-highlights-invited-review-in-american-journal-of-psychiatry-establishing-neuroplasticity-as-a-core-driver-of-psychiatric-disease-and-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933639"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933639\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}